Fuzuloparib , Abiraterone acetate and Prednisone + Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Trial Timeline
Mar 18, 2021 → Dec 31, 2026
NCT ID
NCT04691804About Fuzuloparib , Abiraterone acetate and Prednisone + Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Fuzuloparib , Abiraterone acetate and Prednisone + Fuzuloparib Placebo， Abiraterone acetate and Prednisone is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Metastatic Castration-Resistant Prostate Cancer (mCRPC). The current trial status is active. This product is registered under clinical trial identifier NCT04691804. Target conditions include Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-Resistant Prostate Cancer (mCRPC) were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04691804 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Castration-Resistant Prostate Cancer (mCRPC)